Related Experiment Videos
[Toxicological studies on ipratropiumbromide (author's transl)]
Arzneimittel-Forschung
|January 1, 1976
Summary
Ipratropium bromide (Atrovent) showed typical atropine-like side effects at toxic doses in animal studies. Its low toxicity prevented the determination of an LC50 value.
Area of Science:
- Pharmacology
- Toxicology
- Drug Safety
Context:
- Preclinical assessment of novel therapeutic agents.
- Evaluating the safety profile of anticholinergic compounds.
- Investigating the toxicological effects of ipratropium bromide in animal models.
Purpose:
- To determine the acute, subacute, and chronic toxicity of ipratropium bromide.
- To characterize the toxicological profile across various administration routes and species.
- To establish the safety limits and potential hazards of ipratropium bromide.
Summary:
- Ipratropium bromide (Sch 1000, Atrovent) was evaluated for toxicity in mice, rats, dogs, and monkeys via oral, subcutaneous, intravenous, and inhalation routes.
- Toxic doses induced characteristic atropine-like symptoms, including mydriasis, mucosal dryness, and gastrointestinal disturbances (meteorism, coprostasis).
- The substance exhibited low toxicity, making it impossible to determine a lethal concentration 50 (LC50).
Impact:
- Provides crucial preclinical safety data for ipratropium bromide.
- Informs safe dosage recommendations and clinical use guidelines.
- Highlights the need for careful monitoring of anticholinergic side effects.